P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

FDA Panel Recommends Approval of Degludec Insulin

Cardiovascular outcomes trial will be required (Nov. 9)

The FDA has completed its advisory committee meeting regarding the New Drug Applications (NDAs) for insulin degludec and insulin degludec/insulin aspart (Novo Nordisk).

At the meeting, the committee was asked to discuss the data contained in the NDAs and in subsequent submissions regarding the benefits associated with a lower risk of hypoglycemia and the cardiovascular risk profiles of the two products.

The FDA asked the panel members to vote on whether a cardiovascular outcomes trial should be conducted and on whether sufficient safety and efficacy data had been provided to support marketing of insulin degludec and insulin degludec/insulin aspart.

The committee unanimously recommended that a cardiovascular outcomes trial should be conducted and voted 8 to 4 in favor of approving the products with a post-approval outcomes trial commitment.

The agency has not announced when it expects to complete its review of the NDAs.

Source: Novo Nordisk; November 9, 2012.

More stories